Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis
Source : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1192946/full
BackgroundBreast cancer is the most common cancer type that affects women. In hormone receptor-positive (HR+), human epidermal growth factor receptor 2−negative (HER2-) advanced breast cancer (ABC), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit...
Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37637230/
Prognostic and predictive factors for early and late distant distance recurrence risk in estrogen-receptor positive and HER2-receptor negative early breast cancer are well known, but not all these variables work...
Conclusions: Clearly, until we reach much more and deep understanding of each molecular and phenotypic ER+ subtypes we cannot provide the best benefit with curative intention to every patient. Nowadays, ACT with anthracyclines plus taxanes, AET with AI, EET, and OFS/OA for premenopausal women, abemaciclib or olaparib in selective patients is...
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-11322-2
Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or...
Conclusions: Abemaciclib plus fulvestrant or ribociclib plus AI appear to be effective and relatively safe for the treatment of HR+/HER2- metastatic or advanced BC patients. However, given the reliance on limited evidence, our findings require further validation through additional studies.
Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors - Current Oncology Reports
Source : https://link.springer.com/article/10.1007/s11912-023-01444-y
Purpose of review Sequential use of radiation therapy before cyclin-dependent kinase (CDK) inhibitors in women with early breast cancer seems reasonable and with a low toxicity rate. This study aimed...
Summary: CDK inhibitors applied sequentially and after RT postoperative showed a low profile of acute toxicity and suitable oncological outcomes.
Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37623037/
With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast...
Conclusions/Relevance: This review provides perspectives on some of the challenges related to identification of olaparib candidates, with a focus on the latest guidance for germline BRCA testing and considerations regarding high-risk disease definitions. Updated treatment pathways are explored for both disease states, including other adjuvant...